Privately held Bausch + Lomb Inc. has made ISTA Pharmaceuticals Inc. (NASDAQ: ISTA) an offer it can’t refuse. The eye care company owned by private equity firm Warburg Pincus will acquire ISTA for $9.10/share, or a total of about $380 million.
Last December Valeant Pharmaceuticals Inc. (NYSE: VRX) made a hostile offer of $6.50/share which it eventually raised to $7.50 with a target price of $8.50 provided that the due diligence was completed satisfactorily. ISTA said it would evaluate Valeant’s offer, but would keep its options open. Valeant later withdrew its offer.
The all-cash deal is expected to close in the second quarter.
ISTA’s shares are trading higher in the pre-market this morning, at $9.02 up about 7.6%.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
